CDC Release Health Advisory on Medetomidine in Illicit Fentanyl
Office of National Drug Control Policy
The Office of National Drug Control Policy and the Centers for Disease Control and Prevention have issued a joint health advisory warning of the rapid increase of medetomidine mixed into illicit fentanyl.
Detections of this powerful veterinary sedative, often called "rhino tranq," have surged from 247 in 2023 to 8,233 in 2025, primarily affecting the Northeast and Midwest.
The advisory officially alerts public health professionals and clinicians on how to manage the unique overdose and withdrawal symptoms caused by this chemical.
For those living in impacted communities or working in local healthcare, this represents a severe and evolving public health threat.
Because medetomidine is a sedative not approved for human use, it severely complicates standard overdose responses.
Intoxication causes dangerously low heart rates and prolonged sedation, and withdrawal can trigger severe hypertension, chest pain, and rapid heartbeats.
This means local emergency rooms, first responders, and community health organizations must now rapidly adapt their protocols to handle these specific symptoms.
The federal government is officially mobilizing local healthcare infrastructure to identify and treat this new drug cocktail, highlighting a significant shift in the resources needed to keep communities safe.
